Mark Litton
Chief Executive Officer bei ATHIRA PHARMA, INC.
Vermögen: 449 596 $ am 31.03.2024
Profil
Mark J.
Litton was the founder of Lundbeck Seattle BioPharmaceuticals, Inc. (founded in 2004) where he held the title of Secretary, Treasurer & Chief Business Officer from 2014 to 2018.
He is currently the President, Chief Executive Officer & Director at Athira Pharma, Inc. (since 2019) and also serves as a Director at Lumen Bioscience, Inc. (current job).
In his former positions, Dr. Litton worked as the Manager-Business Development at Sirna Therapeutics, Inc. from 1997 to 1999.
He then served as the Vice President-Business Development at Celltech Group Plc from 1999 to 2004.
He also held the position of Vice President-Business Development at Chiroscience Group Plc.
Additionally, he worked as a Research Associate at DNAX Research, Inc. from 1991 to 1994 and as the President & Chief Operating Officer at Alpine Immune Sciences, Inc. from 2018 to 2019.
Dr. Litton completed his MBA from Santa Clara University in 1994.
He obtained his undergraduate degree from the University of California, Santa Cruz in 1990.
He also holds a doctorate degree from the University of Stockholm, conferred in 1997.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ATHIRA PHARMA, INC.
0,43% | 15.02.2024 | 164 086 ( 0,43% ) | 449 596 $ | 31.03.2024 |
Aktive Positionen von Mark Litton
| Unternehmen | Position | Beginn |
|---|---|---|
| ATHIRA PHARMA, INC. | Chief Executive Officer | 16.06.2021 |
Lumen Bioscience, Inc.
 Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Director/Board Member | - |
Ehemalige bekannte Positionen von Mark Litton
| Unternehmen | Position | Ende |
|---|---|---|
| ALPINE IMMUNE SCIENCES, INC. | President | 16.04.2019 |
| ALDER BIOPHARMACEUTICALS, INC. | Founder | 01.08.2018 |
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Corporate Officer/Principal | 01.01.2004 |
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01.01.1999 |
| DNAX Research, Inc. | Corporate Officer/Principal | 01.01.1994 |
Ausbildung von Mark Litton
| Santa Clara University | Masters Business Admin |
| University of California, Santa Cruz | Undergraduate Degree |
| University of Stockholm | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ATHIRA PHARMA, INC. | Health Technology |
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
| Chiroscience Group Plc | Commercial Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
| DNAX Research, Inc. | |
Lumen Bioscience, Inc.
Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Health Technology |
